Abstract 239MO
Background
We already reported the prognostic role of TILs in HER2+ eBC in the ShortHER trial (distant disease-free survival [DDFS], median follow up: 6 yrs). Here, we present the 10-yr updated analysis including DDFS and OS.
Methods
The ShortHER study randomized 1254 HER2+ eBC patients (pts) to 9 weeks vs 1 yr of adjuvant trastuzumab + chemotherapy (CT). TILs were scored on centralized primary tumor (available for 866 cases). At a median follow up of 9.02 yrs (95% CI 9.00-9.04), the total number of events was 107 for DDFS (24 more than the previously published analysis) and 74 for OS.
Results
In multivariable models including relevant variables (treatment arm, age, menopausal status, stage, histologic grade, hormone receptor status) increased TILs were significantly associated not only with improved DDFS (HR 0.972, 95% CI 0.956-0.989 for each 1% TIL increment, p=0.001) but also with better OS (HR 0.977, 95%CI 0.959-0.996 for each 1% TIL increment, p=0.016). Table shows 10-yr DDFS and OS rates according to different TIL cutoffs. We confirmed the significant interaction between treatment arm and TILs (20% cutoff) for DDFS (p=0.014), with low-TIL pts showing a better outcome with long vs short treatment (10-yr DDFS 88.7% vs 81.0%, p=0.006), and high-TIL pts showing the opposite (10-yr DDFS 87.1% vs 92.2% for long vs short, p=0.091). Regarding OS, pts with TILs≥20% had 10-yr OS rate of 89.3% vs 93.1% in long vs short arm (HR short vs long 0.36 95%CI 0.10-1.36, p=0.131). For pts with TILs
Conclusions
This is the first demonstration of an independent prognostic role of TILs in terms of OS for HER2+ eBC pts treated with adjuvant CT and anti-HER2. Our data suggest that pts with TILs≥20% de-escalating trastuzumab duration are not exposed to an excess risk of death. These data further support the inclusion of immune biomarkers into prognostic tools for HER2+ eBC.
Clinical trial identification
NCT00629278.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AIFA (FARMS5KR) and AIRC (MFAG-15938).
Disclosure
M.V. Dieci: Financial Interests, Personal, Advisory Board: Novartis, Eli lilly, Seagen, Exact Science, Daiichi Sankyo, Gilead, reveal genomics; Financial Interests, Personal, Other, Consultancy: Pfizer; Financial Interests, Personal, Invited Speaker: Exact sciences, Gilead, Seagen, Daiichi Sankyo, Novartis, Eli lilly; Financial Interests, Personal, Other, Consultancy on educational project: Roche. A. Musolino: Financial Interests, Personal, Advisory Board: Roche, Novartis, Gilead, AstraZeneca; Financial Interests, Institutional, Coordinating PI: Roche; Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institutional, Funding: Seagen; Non-Financial Interests, Principal Investigator: Roche, Lilly, Gilead, Novartis. O. Garrone: Financial Interests, Personal, Advisory Board, outside the submitted work: MSD, EISAI, Pfizer; Financial Interests, Personal, Invited Speaker, outside the submitted work: Novartis, Lilly, Daiichi Sankyo, AstraZeneca. A. Ferro: Financial Interests, Personal, Invited Speaker, outside the submitted work: Lilly, Novartis, Pierre-Fabre. F. Miglietta: Financial Interests, Personal, Invited Speaker: Roche, Novartis, Seagen, Pfizer, Lilli; Financial Interests, Personal, Advisory Board: Astrazeneca, MSD; Financial Interests, Personal, Writing Engagement: Menarini. V. Guarneri: Financial Interests, Personal, Invited Speaker: EliLilly, Novartis, GSK, AstraZeneca, Gilead, Exact Sciences; Financial Interests, Personal, Advisory Board: EliLilly, Novartis, MSD, Gilead, EliLilly, merck serono, Exact Sciences, Eisai, Olema Oncology, AstraZeneca, Daiichi Sankyo, Pfizer; Financial Interests, Institutional, Local PI: EliLilly, Roche, BMS, Novartis, AstraZeneca, MSD, Synton Biopharmaceuticals, Merck, GSK, Daiichi Sankyo, Nerviano, Pfizer; Non-Financial Interests, Member: ASCO. All other authors have declared no conflicts of interest.
Resources from the same session
233MO - Ovarian function suppression in HR-positive, HER2-positive breast cancer: An exploratory analysis from the HERA trial
Presenter: Sung Gwe Ahn
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
234MO - Explaining the relationships between age, endocrine therapy persistence and risk of recurrence in hormone-positive early breast cancer: A nationwide cohort study
Presenter: Elise Dumas
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
235MO - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Presenter: Sherene Loi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Invited Discussant 233MO, 234MO and 235MO
Presenter: Kevin Kalinsky
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast
236MO - Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study
Presenter: Manon de Graaf
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
237MO - TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy
Presenter: Miguel Martin Jimenez
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
238MO - PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
Presenter: Francois Cherifi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA14 - Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
Presenter: Sabine Linn
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant 236MO, 237MO, 238MO and LBA14
Presenter: Lisa Carey
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast
LBA15 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Presenter: Meghna Trivedi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast